NasdaqGM:PRQR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has ProQR Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRQR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.2%

PRQR

3.1%

US Biotechs

4.0%

US Market


1 Year Return

-38.0%

PRQR

24.2%

US Biotechs

5.0%

US Market

Return vs Industry: PRQR underperformed the US Biotechs industry which returned 22.8% over the past year.

Return vs Market: PRQR underperformed the US Market which returned 4.8% over the past year.


Shareholder returns

PRQRIndustryMarket
7 Day-6.2%3.1%4.0%
30 Day7.9%7.0%0.9%
90 Day27.1%31.2%29.5%
1 Year-38.0%-38.0%25.5%24.2%7.2%5.0%
3 Year10.0%10.0%32.8%28.4%36.2%27.3%
5 Year-66.2%-66.2%0.04%-5.7%65.4%47.0%

Price Volatility Vs. Market

How volatile is ProQR Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ProQR Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRQR ($5.72) is trading below our estimate of fair value ($104.99)

Significantly Below Fair Value: PRQR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PRQR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PRQR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRQR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRQR is good value based on its PB Ratio (3.1x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is ProQR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

41.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRQR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRQR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRQR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PRQR's revenue (77.9% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: PRQR's revenue (77.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRQR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ProQR Therapeutics performed over the past 5 years?

-19.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRQR is currently unprofitable.

Growing Profit Margin: PRQR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRQR is unprofitable, and losses have increased over the past 5 years at a rate of -19.7% per year.

Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: PRQR has a negative Return on Equity (-72.01%), as it is currently unprofitable.


Next Steps

Financial Health

How is ProQR Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PRQR's short term assets (€101.0M) exceed its short term liabilities (€9.2M).

Long Term Liabilities: PRQR's short term assets (€101.0M) exceed its long term liabilities (€13.1M).


Debt to Equity History and Analysis

Debt Level: PRQR's debt to equity ratio (16%) is considered satisfactory.

Reducing Debt: PRQR's debt to equity ratio has increased from 2.6% to 16% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRQR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PRQR has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 17.4% each year.


Next Steps

Dividend

What is ProQR Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRQR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRQR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRQR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRQR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRQR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Daniel de Boer (37yo)

8.42yrs

Tenure

€2,265,000

Compensation

Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. Mr. de Boer is responsible for the overall strategy and gene ...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD2.55M) is above average for companies of similar size in the US market ($USD1.35M).

Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel de Boer
CEO & Member of Management Board8.42yrs€2.27mno data
Smital Shah
Chief Business & Financial Officer5.75yrsno datano data
Lisa Hayes
Vice President of Investor Relations & Corporate Communications1.58yrsno datano data
Bart Klein
Senior Vice President of Intellectual Propertyno datano datano data
Gerard Platenburg
Chief Innovation Officer & Chairman of Advisory Board2.92yrs€34.00kno data
Bianca Matthee
Head of Manufacturing and Pharmaceuticsno datano datano data
David Rodman
Executive Vice President of Research & Developmentno datano datano data
Peter Adamson
Senior Vice President of Ophthalmology Franchise2.75yrsno datano data
Aniz Girach
Chief Medical Officer1.58yrsno datano data
Tiffany Burt
Head of Commercial & VP1.58yrsno datano data

2.8yrs

Average Tenure

50yo

Average Age

Experienced Management: PRQR's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gerard Platenburg
Chief Innovation Officer & Chairman of Advisory Board2.92yrs€34.00kno data
Antoine Papiernik-Berkhauer
Independent Member of Supervisory Board6.5yrs€104.00kno data
Cy Stein
Member of Scientific Advisory Board3.08yrsno datano data
Arthur Levin
Member of Scientific Advisory Boardno datano datano data
Alison Lawton
Independent Member of Supervisory Board5.83yrs€148.00kno data
Phillip Zamore
Member of Scientific Advisory Board3.08yrsno datano data
James Shannon
Independent Member of Supervisory Board4.08yrs€157.00k0.12% 352.0k
Domenico Valerio
Independent Chairman of Supervisory Boardno data€180.00k0.78% 2.2m
Bart Filius
Supervisory Board Member1.17yrs€56.00kno data
Annemieke Rus
Member of Scientific Advisory Board3.08yrsno datano data

3.1yrs

Average Tenure

61.5yo

Average Age

Experienced Board: PRQR's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.


Top Shareholders

Company Information

ProQR Therapeutics N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ProQR Therapeutics N.V.
  • Ticker: PRQR
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$286.116m
  • Shares outstanding: 50.02m
  • Website: https://www.proqr.com

Number of Employees


Location

  • ProQR Therapeutics N.V.
  • Zernikedreef 9
  • Leiden
  • Zuid-Holland
  • 2333 Ck
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRQRNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDSep 2014

Biography

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber’s congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 00:19
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.